May 19, 2022 — The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. The findings show clinical characteristics and management strategies differ by gender, but in-hospital mortality rates remained high among both groups. The findings were simultaneously published in JSCAI.
In the United States, someone experiences a heart attack every 40 seconds (CDC). Of these patients, more than 25% will experience a more severe type of heart attack, an ST-elevated myocardial infarction, or STEMI caused by the sudden, total blockage of a coronary artery. Pre-COVID-19 mortality in STEMI patients was below 5% (JACC). Research is underway to better understand the effects of COVID-19 on cardiovascular diseases and outcomes.
In this analysis, the authors compared clinical characteristics, management strategies and outcomes of male and female STEMI patients with COVID-19 patients. Among 585 with STEMI and COVID-19, 154 (26.3%) were female.
Compared to males, females were significantly older, had higher rates of diabetes and stroke/TIA and statin on admission. Males were more likely to present with chest pain whereas females presented with dyspnea, or labored breathing. Females more often had STEMI without an identified culprit lesion. Use of primary percutaneous coronary intervention (PCI) was significantly higher in males, whereas medical therapy was higher in females. In-hospital mortality was 33% for females and 27% for males (p=0.217); there were also no significant sex differences in-hospital stroke or re-infarction, or composite primary endpoint.
“The significant increase in mortality among both men and women in this study highlights the need for continued research to better understand the long-term effects of COVID-19 on cardiovascular health,” said Odayme Quesada, MD, Medical Director at The Christ Hospital Women’s Heart Center in Cincinnati, OH. “Our study also points to the lack of research and clear guidance on how to treat STEMI patients without an identified culprit lesion, many of which are women. We hope additional analysis of these patient characteristics will help further inform clinicians on best the treatment approach and ultimately improve patient outcomes.”
The NACMI registry is a collaboration between SCAI, the American College of Cardiology and the Canadian Association of Interventional Cardiology. The registry was established in 2020 with the aim to define baseline characteristics and management strategies and outcome data for COVID-19 patients presenting with STEMI. More than 60 medical centers across North America and Canada contributed data to the registry.
Researchers note that further investigation is needed to better understand sex-differences in the underlaying etiology of STEMI.
“Sex Differences in Clinical Characteristics, Management Strategies and Outcomes of STEMI Patients with COVID-19.” [May 19, 2022, 9 – 9:10 a.m. ET, Centennial I, Ballroom Level - LL1]
For more information: https://scai.org/scai2022
Find more SCAI22 coverage here
Related COVID-19 Cardiology Content:
In-Hospital Deaths in STEMI Patients With COVID-19 Drop in 2021
The Long-term Cardiovascular Impact of COVID-19
COVID-19 Changes Properties Blood Cells
VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients — Interview with Behnood Bikdeli M.D.
Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?
PHOTO GALLERY: How COVID-19 Appears on Medical Imaging
Heart Damage Found in More Than Half of COVID-19 Patients Discharged From Hospitals
Overview of Randomized Trials of Antithrombotic Therapy for COVID-19 Patients
COVID-19 Can Kill Heart Cells and Interfere With Contraction